礼来与武田制药遭法律策略锁定，通常此类手段仅用于打击黑帮。
Lilly, Takeda targeted by legal strategy usually reserved for the mob
生命科学资讯
生物技术与制药领域的最新动态
德克萨斯、北卡罗来纳、俄亥俄、宾夕法尼亚——制药制造业投资激增之地
Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged
特朗普公布医疗可负担性计划
Trump unveils healthcare affordability plan
制药高管关注的临床候选药物
The clinical candidates pharma execs are tracking
美国生物制药并购迎来关键时刻，药企能否克服持续焦虑达成交易？
It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?
礼来与诺和诺德测试直供雇主模式，或可绕过药品福利管理公司降低成本。
Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
马萨诸塞州生物制药行业呈现三大积极趋势
3 positive trends for Massachusetts’ biopharma sector
一家生物科技公司的蛇咬药丸引起美军兴趣。
A biotech’s snakebite pill is drawing the US military’s interest
赛诺菲多发性硬化症困境对行业意味着什么
What Sanofi’s multiple sclerosis troubles could mean for the space
PharmaVoice的水晶球：人工智能与药物研发的未来走向
PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D
健康产业成为美国卫生与公众服务部的新宠。
The wellness industry is HHS’ new belle of the ball
亿万富翁肖恩·帕克已撼动癌症研发领域，他的非营利组织能否填补资金缺口？
Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?
高管层优先事项揭示AI在制药业的未来前景
C-suite priorities give a sneak peek into AI’s pharma future
2026年值得关注的5项FDA药物审批
5 FDA drug approvals to watch in 2026
PharmaVoice展望：塑造医药行业的市场与政策力量
PharmaVoice’s Crystal Ball: Market and policy forces shaping the industry
中国最具创新力的三家制药公司
3 of China’s most innovative pharma companies
超越肉毒杆菌：艾伯维在神经毒素研发领域寻求更广泛突破
Beyond Botox: AbbVie’s push for broader gains in neurotoxin R&D
美国生物制药公司CEO的乐观情绪正在动摇。
Biopharma CEO optimism is wavering in the U.S.
百健首席信息官押注技术与人工智能革新，为增长“铺平高速公路”。
Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth
制药业肥胖药竞赛中的主要GLP-1竞争者
The leading GLP-1 contenders in pharma’s race for an obesity pill